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Prophylaxis and therapy for viral hemorrhagic fevers Monath 825
Cbem 1972, 15:1150-1154). Activity has been demonAlthough the anemia and other adverse reactions noted strated against many DNA and RNA viruses, with a previously do not limit use of the drug for treatment of wide separation of cytotoxic and viral inhibitory activserious viral infections, they assume another dimension ities (Smith and Kirkpatrick, eds., Ribavirin, A Broad- in the prophylactic use of ribavirin. The administration Spectrum Antitvral Agent. Academic Press, 1980). In of ribavirin to healthy individuals or those exposed to clinical trials conducted since 1977, ribavirin has been self-limited viral infections must also take into account administered to more than 1000 cancer patients and certain toxic effects of ribavirin described only in exmore than 2000 patients with various viral infections, perimental animals, including teratogenicity and fetoincluding influenza, measles, hepatitis A, B, and C, and toxicity (clearly established in rabbits and rodents), tesherpes (Fernandez, in Smith and Kirkpatrick, eds. Ribticular atrophy (inconclusive in rodents), and carcinoavirin, A Broad-Spectrum Antivtral Agent. Academic genicity (inconclusive in rodents). Use of the drug in Press, 1980, pp 215-232; Smith et at, eds. , Clinical Apwomen of child-bearing age requires that pregnancy plications of Ribavirn. Academic Press, 1984) .
be excluded, not only during the course of treatment, but during drug washout, which is prolonged. ProThe efficacy of ribavirin administered as a small particle phylaxis (and treatment) of pregnant women assumes aerosol against respiratory syncytial virus was demonits greatest importance in the case of Lassa fever (disstrated in experimentally infected adults (Hall et at, cussed in a later section). Further studies on the ques-N EnglJ Med 1983 Med , 308:1443 Med -1447 , leading to licentions of testicular damage (and its reversability) and of sure of the drug for this indication in the United States.
carcinogenicity are currently underway in rodents. The oral formulation is approved for use against in-
The pharmacodynamics of ribavirin in humans have fluenza, hepatitis, and herpesvirus infections in many been studied after intravenous (Austin et al., Antimicountries, but rigorous delineation of efficacy is still recrob Agents Cbemother 1983, 5:696-701; Laskin et al, quired. The drug is still under study in human immunClin Pharmacol Ther 1987, 41:546-555) and oral adodeficiency virus-infected patients; despite in vitro acministration (Roberts et al., Clin Pharmacol Ther 1987 , tivity against human immunodeficiency virus, ribavirin 42:365-373). Several points emerge that are relevant to has not suppressed antigenemia or caused immunothe viral hemorrhagic fevers. After a single intravenous logic improvement (Roberts et al, AIDS 1990, 4:67-72;  administration of 2400 mg (the loading dose used for Schulof et al.,JADS 1990, 3:485-492) . Intravenous ribtreating hemorrhagic fever patients), the mean peak avirin has been evaluated principally for the treatment (0.5-hour) serum concentration was 40 gg/mL. In Lassa of viral hemorrhagic fevers (as described in the folfever patients treated for 4 days with 1000 mg every 6 lowing sections), but limited trials have also been rehours, the mean level 2.5 hours after the dose was 8 ported against herpes zoster (Lorenco et at, Rev Bras gg/mL. These levels are within the range for inhibition Med 1977, 33:401-403) and influenza myocarditis (Ray of arena-and bunyaviruses in cell culture (Table 2) .
et al J Infect Dis 1989, 159:829-836) .
The inhibitory effect of ribavirin is highly host-cell deExtensive human use has supported the safety of ribpendent, probably because of differences in the ability avirin. The most important documented adverse efto phosphorylate the drug to its active form. Vero cells fect in humans is anemia due to inhibition of eryare among the most resistant cell types. throcyte maturation in bone marrow and to periphMoreover, plasma levels may not accurately reflect ineral hemolysis (Canonico, in Hahn, ed. Antibiotics, Vol tracellular concentrations of ribavirin, which is a pro-17, Modes and Mechanisms of Microbial Growth In- drug requiring phosphorylation by cellular enzymes for hibitors. Springer-Verlag, 1983, pp 160-186) . These efits antiviral action. The drug is concentrated in erythrofects are dose-dependent and completely reversible on cytes in phosphorylated forms, accumulates with recessation of therapy. In a study of human immunodpeated dosing, and has a very long elimination halfeficiency virus-infected men with lymphadenopathy, life (> 2 weeks) corresponding to the life-span of eryRoberts et al (Gin Pharmacol 7her 1987, 42:365-373) throcytes. The long terminal half-life of ribavirin, its ennoted reductions in hematocrit of 0, 4, and 12 points trapment within erythrocytes, and prolonged time rein subjects respectively receiving 600, 1200, and 2400 quired to reach steady-state conditions, are indications mg/d for 2 weeks. Patients treated for as long as 24 for use of a loading dose and frequent schedule of inweeks developed a compensatory reticulocytosis, with travenous drug administration when treating life-threatstabilization of the anemia after its nadir at 2 to 3 weeks ening acute infections. of therapy; the hematocrit rapidly returned to normal Only about 25% of the drug is excreted in urine, after cessation of the drug therapy. A higher incidence and the drug is not significantly cleared by hemodialof subjective complaints, ie, gastrointestinal symptoms ysis (Kramer et al., Antimicrob Agents Chemotber (flatulence and nausea), metallic taste, and central ner-1990, 34:489-490) . Thus, the dose does not have to vous system symptoms (headache, insomnia, and fabe adjusted in patients with renal failure, an importigue), was noted among treated patients. Although not tant point for patients with some hemorrhagic fevers. statistically different from the reactions of placebo conRibavirin is primarily eliminated by metabolic pathtrols at daily doses of 1200 mg or less, these reactions ways, and high concentrations are found in liver tiswere moderately severe at daily doses of 2400 mg, resue (Ferrara et al., Antimicrob Agents Chemother 1981 , quiring cessation of therapy in some patients.
19:1042-1049), a critical target organ for many hem- open-label trials in which mortality in treated patients Congo-Crimean hemorraghic fever (CCHF) virus (1 to was compared with that in historical controls; more-20 pg/mL) and lower sensitivity of phleboviruses, eg, over, a retrospective reanalysis of data on a subset Rift Valley fever and sandfly fever (40 to 80 Ig/mL) [4] .
of patients was performed after fatal-outcome predicRibavirin is not effective against the filoviruses, Ebola, tors were identified (aspartate aminotransferase levels, and Marburg virus diseases. Flaviviruses require con-> 150 IU/L; or viremia. > 3.6 lOgl0; median tissue culture centrations (250 to 400 gg/mL) that are generally not infective dose, 50/mL). Despite these shortcomings in achievable with nontoxic doses in tvro.
design and analysis, a convincing case was made for efficacy of ribavirin. The best survival was observed in Arenavirus diseases patients treated on or before the sixth day of illness Lassa fever with intravenous drug. In the subset of patients with Lassa fever is an acute infection characterized by fever, the worst prognosis (viremia, > 3.6 logs), the case-fatalheadache, myalgia, pharyngitis, vomiting, a relatively it rate was 9% in patients treated with intravenous ribmild hemorrhagic diathesis, a capillary leak syndrome avirn and 200% in those given the drug orally, as comwith facial edema, adult respiratory distress syndrome, pared with 75% in untreated (historical) controls. shock, and multiple organ failure (McCormick et al, J Convalescent plasma was not efficacious. However, Infect Dis 1987, 155:445-455) . Eighth nerve deafness is this finding may have been due to the absence or low an important complication in surviving patients.
titers of neutralizing antibodies in convalescent plasan estimas used in this study. Neutralizing antibodies may not Lassa fever is endemic in West Africa, where a es, be detectable until months after infection, and careful mated 300,000 human infections, 30,000 clinical cases, selection of convalescent plasma is required to yield and 5000 deaths occur annually ( and more than a third of all deaths on medical wards Combined use of ribavirin and potent plasma rescued of hospitals in endemic areas are due to the disease, monkeys in which treatment was begun as late as with a case-fatality rate in hospitals of 16%. A number 10 days after infection (when either treatment alone of nosocomial outbreaks have been described in which was unsuccessful). These results may be relevant to hospital staff and patients became infected by contact the clinical situation, especially to antibody treatment or possibly aerosol exposure to an index case (Monath of pregnant women (in whom ribavirin is contraindi- 1986, 314:20-26) . Given the apparent were delayed, probably reflecting the profound suplow risk of contagion, close medical surveillance and pression of virus replication rather than drug-induced early treatment of compatible febrile illness with intraimmunomodulation. When ribavirin was initiated at the venous ribavirin may be an acceptable strategy for all time of onset of fever or viremia (postinfection days but those with the highest risk of infection, eg, those 4 to 7), animals were rescued from the acute hemwith a needle-stick injury or direct blood contact with orrhagic phase of illness and had blunted viremias, mucous membranes or broken skin.
but approximately 75% succumbed to late-onset encephalitis. Virus is readily recoverable from the central Two final points relating to ribavirin therapy should be nervous system of untreated animals that die of vismentioned. First, Lassa fever is an especially severe incerotropic, hemorrhagic infection but has very rarely fection in pregnant women [6] . Fetal loss is 92% during been demonstrated in monkeys dying of late neurothe first and second trimesters and 75% in the third, logic syndrome. The exact time of viral neuroinvasion and the risk of maternal death is significantly higher in has not been established, but neuroinvasion probathe third trimester than earlier in pregnancy or in nonbly occurs as viremia levels escalate during the second pregnant women. Since termination of pregnancy and week after infection. Delay in treatment with ribavirin, uterine evacuation significantly improve survival, this which does not readily enter the central nervous syscourse of action is recommended prior to therapy with tem, allows clinical expression of encephalitis. Treatribavirin. Second, antiviral treatment of experimental ment of monkeys and guinea pigs with immune plasma and human Lassa fever has not been associated with also induces late neurologic syndrome. late encephalitis or encephalopathy, as described in the These events have correlates in human medicine. Conother arenaviral hemorrhagic fevers. This observation valescent plasma containing a high titer of neutralizmay reflect a lower neurotropism of Lassa virus.
ing antibodies is highly effective in reducing mortality Argentine and Bolivian hemorrhagic fevers (to < 1%) if given within 8 days of onset and constiThe Argentine and Bolivian hemorrhagic fevers, which tutes standard therapy for Argentine hemorrhagic fever are rodent-borne South American fevers, share clini- (Maiztegui et al., Lancet 1979 , ii:1216 -1217 ; Enria et al, cal features with Lassa'fever but have more promiLancet 1984, ii:255-256). In the South American hemnent neurologic symptoms and hemorrhagic manifesorrhagic fevers, in contrast to Lassa fever, neutralizing tations. The case-fatality ratio in both diseases is apantibodies appear relatively early and, with compleproximately 10% to 15%, with deaths occurring from ment, play an important role in viral clearance and reirreversible shock during the second week of illness.
covery from infection. However, antibody therapy is Argentine hemorrhagic fever, caused byJunin virus, ocassociated with the appearance of late neurologic syncurs in an endemic, localized region of Buenos Aires drome several weeks after recovery in 8.6% of patients, and C6rdoba Provinces, with an annual incidence of whereas this complication has not been observed in several hundred case. and cyclic epidemics with up to untreated survivors (Enria et al., Med Microbial Im- munol 1986, 175:173-176). Late neurologic syndrome ment with plasma or administration of ribavirin rediffers from the severe neurologic syndrome seen durduces interferonemia. Administration of exogenous ining the acute phase and is generally characterized by terferon to patients with arenaviral infections would fever and benign cerebellar signs. vere, with a case-fatality rate of 5% to 10%, whereas Three of 6 patients died, but the time to death was prothe urban form is milder (case-fatality, < 1%). In Scanlonged and both the disappearance of viremia and a danavia and parts of western Europe, a related virus decline in serum interferon levels were attributed to (Puumala) transmitted by voles causes hundreds to treatment. Although virus is recoverable from blood thousands of cases of a generally benign form (caseand liver in more than 80% of untreated patients at fatality, <0.5%), referred to as nephropatbia epidemthe time of death, no virus was detectable in tissues ica. Seoul-like viruses have been widely disseminated from the ribavirin-treated patients. The febrile phase (lasting 3 for 6 days) was subsequently initiated. A total of 18 pato 7 days) is characterized by fever, myalgia, gastrotients entered the study, all with at least 9 days of illness intestinal symptoms, renal pain and tenderness, and prior to entry (beyond the point at which therapy with signs of vascular dysregulation. This phase is followed immune plasma is efficacious). Although not statistiby a bypotensivepbase (lasting several hours to 3 days), cally significant, mortality was lower in the ribavirinwith capillary leak syndrome, hemoconcentration, hytreated group. No treatment effect on viremia or inpotension, shock, proteinuria, and hemorrhagic pheterferon levels was observed in this study (McKee and nomena; approximately one third of the deaths occur Maiztegui, Personal communication).
during this phase. The oliguric phase, lasting 3 to 7
Arenaviruses, including Lassa fever and the South days, is characterized by renal failure, hypertension, seAmerican hemorrhagic fevers, are resistant to the acvere hemorrhagic manifestations, metabolic, and election of interferon alpha , despite its induction of high trolyte derangements, and pulmonary edema, and aclevels of antiviral enzymes (2'5'-oligoadenylate syncounts for more than 50% of the deaths. A diuretic thetase). Whether interferon itself plays a pathogenic phase follows, with recovery from renal tubular necrorole is unclear. In a guinea pig model of hemorrhagic sis. Convalescence may be prolonged, often requiring fever, treatment with interferon or an interferon inmonths for full return to health. No animal model of ducer had neither a beneficial nor an adverse effect this disease process has been discovered. Press, 1988, pp 117-222) . The disease is sporadic, ac-9:183). Preclinical evaluation of ribavirin had shown quired by tick-bite and occupational exposure to blood high in vitro sensitivity of Hantaan virus and a posiof infected livestock, and of low incidence. However, tive treatment effect in suckling mice (Huggins et al., an important epidemiologic feature of CCHF is the oc-J Infect Dis 1986, 153:489-497) and severe combined currence of nosocomial outbreaks. In these situations, immunodeficiency disease mice (Zhang and Huggins, an index case patient admitted to hospital with hemAntiviral Res 1990, [suppl 11:120) . This evidence led orrhage undergoes surgery or rescuscitative measures, to a technically difficult, placebo-controlled, doubleexposing medical staff to blood. rhage, DIC, shock, multiple organ failure, and a casemay be specifically diagnosed by a rapid serologic test fatality of 300/6. Patients with fatal cases are viremic until (gM enzyme-linked immunosorbent assay). death and have absent or delayed antibody responses Ribavirin was administered intravenously in a dose cor-[81, suggesting a role for passive antibody treatment responding to that used in Lassa and Argenitine hemand antiviral therapy. Moreover, laboratory parameters, orrhagic fever patients (loading dose of 33 mg/kg, folincluding elevated serum transaminase levels, high tolowed by 16 mg/kg every 6 hours for 4 days, then tal leukocyte count, and various indicators of DIC are 8 mg/kg every 8 hours for 6 days). Treated patients predictive of fatal outcome [91 and provide a means for had a reduction in mortality (2.4% vs 8.6% in placeboassessing drug efficacy. Early, rapid diagnosis may be receiving controls; P= 0.01); when these figures were achieved by detecting circulating antigen by immunocorrected for baseline variables predictive of fatal outassay or reverse hemagglutination. come (total serum protein and aspartate aminotransCongo-Crimean hemorrhagic fever virus infectivity is ferase levels), a seven-fold reduction was found in risk inhibited in vitro by low concentrations of ribavirin [31. of death in the treated group. Statistically significant reThe efficacy of ribavirin against CCHF virus in vivo has ductions were also demonstrated in the frequency of been demonstrated in suckling mice, the only suscepoliguria, in serum creatinine levels, in the risk of hemtible animal model (Berezina et al., Vopr Vlrusol 1983, orrhage, and in the duration of hypertension. The di-5:627-629; Tignor, Personal communication). Signifiuretic phase was significantly foreshortened in treated cant protection was achieved with doses of 100 mg/kg patients. The only ad' erse effect related to treatment administered as late as 48 hours after infection and with was the occurrence of anemia, which was not of suffilower doses (25 mg/kg) in a prophylactic model. cient magnitude to require interruption of therapy. RibExperience with ribavirin treatment of human patients avirin treatment also decreased the frequency and titer with CCHF is very limited. In a nosocomial outbreak in of detectable viremia, as compared with these parameters in control subjects given placebo (Yang et al.,
South Africa in 1984, the drug was administered proChung Hua IHsueh Tsa C/j~b 1989, 69:621-625 [in Chiphylactically to six of nine case-contacts who had susnese]1, tained direct blood exposure (eg, needle-pricks); three individuals also received a short course of interfe:on. A placebo-controlled, blinded trial of recombinant inRibavirin (a minimum of 10 mg/kg every 8 hours) was terferon alpha was conducted in Chinese patients with administered by the intravenous route for one incubamoderate or severe HFRS (Gui et al, J Infect Dis tion period (8 days) after exposure (Van de Wal et at, 1987 , 155:1047 -1051 . No clear benefit was observed S Afr MedJ 1985, 68:729-732) . One of the six treated in most parameters measured, although bleeding mancontacts developed a mild case of CCHF; she had not ifestations and proteinuria were significantly less in received interferon. All three untreated contacts develthe treated patients. Mortality was 16% in treated and oped severe CCHF. Mauritania (1987) and Madadoses of exogenous interferon alpha protected mongascar (1990). The typical human disease is charackeys against viremia, hepatic dysfunction, and coaguterized by a nonspecific but severe febrile syndrome lopathy (12], and interferon inducers are effective in roof 4 to 7 days' duration; however, approximately 1% dent models. Synergism in rodent models between ribof infections result in severe or complicated illness avirin and immunomodulators, including poly (ICLC) with hemorrhagic fever, encephalitis, or retinitis. Mor-(Kende et at., Adv Biosci 1988, 68:51-63) , suggests intality rates in affected populations have ranged beteresting approaches to prophylaxis and therapy in hutween 0.3% and 0.5%. The case-fatality rate in Egyptian mans. hospitals was 11% to 14%, accounted for mainly by paNo human trials of ribavirin, interferon, or combined tients with hemorrhage, severe liver dysfunction, and therapy have yet been conducted. Clinical studies shock. Viremia titers are high, and rapid, early diagnowould certainly be appropriate in the event of a future sis of up to one third of human cases may be achieved epidemic. To better define the appropriate dose and by enzyme-linked immunosorbent assay detection of schedule of prophylactic and therapeutic approaches, antigen in serum or by nucleic acid hybridization; apthe sandfly fever clinical model will prove useful. This plication of the polymerase chain reaction has not yet self-limited febrile disease, caused by a phlebovirus rebeen reported. lated to Rift Valley fever virus, has long been used livestock in 14, and nosocomial spread in 7. The case-fatality rate was body, whereas interferon may be pathogenic in arenavinis infections 30% with deaths due to multiple-organ failure. Liver necrosis was and cellular immunity, not antibody, is responsible for arenavirus a prominent feature, and some patients became overtly jaundiced.
clearance. Direct viral cytolysis underlies injury in Rift Valley fever, Severe bleeding diathesis, marked thrombocytopena, and disseriwhereas Lassa fever pathogenesis may be indirect, involving soluble nated intravascular coagulation were features of the disease. 
